Human PlGF Quantikine ELISA Kit

  (56 citations)     
Datasheet / CoA / SDS
Product Details
Assay Procedure
Citations (56)
FAQs
Supplemental Products
Reviews
  • Assay Type
    Solid Phase Sandwich ELISA
  • Format
    96-well strip plate
  • Assay Length
    3.5 hours or 4.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (100 uL), Serum (100 uL), EDTA Plasma (100 uL), Heparin Plasma (100 uL), Citrate Plasma (100 uL), Urine (100 uL)
  • Sensitivity
    7 pg/mL
  • Assay Range
    15.6 - 1,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Citrate Plasma, Urine)
  • Specificity
    Natural and recombinant human PlGF
  • Cross-reactivity
    Cross-reactivity observed with 1 or more available related molecules.Cross-species reactivity not tested.
  • Interference
    Interference observed with 1 or more available related molecules.
Control Available
QC22 , Quantikine Immunoassay Control Group 7 - Please Inquire
Product Summary
The Quantikine Human PlGF Immunoassay is a 3.5 or 4.5 hour solid phase ELISA designed to measure human PlGF in cell culture supernates, serum, plasma, and urine. The immunoassay kit contains E. coli-expressed recombinant human PlGF and antibodies raised against the recombinant factor. This immunoassay has been shown to quantitate recombinant human PlGF accurately. Results obtained using natural human PlGF showed dose curves that were parallel to the standard curves obtained using the recombinant Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural human PlGF.

Precision
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision
Cell Culture Supernates
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 40.9 138 541 46.9 149 555
Standard Deviation 2.4 7.3 38.2 6.4 13.5 32.9
CV% 5.9 5.3 7.1 13.6 9.1 5.9

Serum, EDTA Plasma, Heparin Plasma, Citrate Plasma, Urine
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 54.3 175 658 55 184 724
Standard Deviation 3.8 6.3 36.9 6.5 20.3 78.9
CV% 7 3.6 5.6 11.8 11 10.9

Recovery

The recovery of PlGF spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=5) 97 82-107
Citrate Plasma (n=5) 99 93-120
EDTA Plasma (n=5) 102 92-117
Heparin Plasma (n=5) 94 81-113
Serum (n=5) 96 88-118
Urine (n=4) 97 85-112
Linearity
To assess the linearity of the assay, five samples were spiked with high concentrations of PlGF in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
 PLGF [HRP]
Product Datasheets

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Certificate of Analysis Lookup

Certificate of Analysis Request Form

To download a Certificate of Analysis, please enter the catalog and lot numbers in the search box below.

Note: Certificate of Analysis not available for kit components.

Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: PlGF
PlGF (placenta growth factor) is a homodimeric growth factor that competes with VEGF for binding to VEGF R1/Flt-1. It therefore increases the availability of VEGF to bind to VEGF R2/KDR/Flk-1 and trigger angiogenesis. It can form heterodimers with some forms of VEGF and decrease the angiogenic effect of VEGF on VEGF R2. Circulating PlGF levels increase during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. PlGF induces monocyte activation and migration as well as production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis. PlGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension.
  • Long Name:
    Placenta Growth Factor
  • Entrez Gene IDs:
    5228 (Human); 18654 (Mouse)
  • Alternate Names:
    D12S1900; PGF; PGFL; placenta growth factor; placental growth factor; placental growth factor, vascular endothelial growth factor-related protein; PlGF; PlGF-2; PLGFplacental growth factor-like; SHGC-10760
Related Research Areas
Assay Procedure
Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 100 µL Standard, Control, or Sample
  6.   Add 100 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well.
  10.   For Serum, Plasma, & Urine Samples: Cover with a new plate sealer, and incubate at room temperature for 2 hours.
    For Cell Culture Supernate Samples: Cover with a new plate sealer, and incubate at room temperature for 1 hour.
  11.   Aspirate and wash 4 times.

  12. 200 µL Substrate Solution
  13.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes. PROTECT FROM LIGHT.

  14. 50 µL Stop Solution
  15. Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.
Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

56 Citations: Showing 1 - 10
Filter your results:

Species
Sample Type
  1. Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients
    Authors: T Tsai, S Kuehn, N Tsiampalis, MK Vu, V Kakkassery, G Stute, HB Dick, SC Joachim
    PLoS ONE, 2018;13(3):e0194603.
    Species: Human
    Sample Type: Vitreous Humor
  2. Inverted formin 2 regulates intracellular trafficking, placentation, and pregnancy outcome
    Authors: KYB Lamm, ML Johnson, J Baker Phil, MB Muntiferin, JM James, HN Jones, RW Redline, A Rokas, LJ Muglia
    Elife, 2018;7(0):.
    Species: Human
    Sample Type: Cell Culture Supernates
  3. Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles
    Authors: M O'Brien, D Baczyk, JC Kingdom
    Sci Rep, 2017;7(1):5887.
    Species: Human
    Sample Type: Tissue Culture Supernates
  4. Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease
    Authors: X Li, QY Yao, HC Liu, QW Jin, BL Xu, SC Zhang, CT Tu
    J. Cell. Mol. Med., 2017;0(0):.
    Species: Human
    Sample Type: Serum
  5. Elevated expression of placental growth factor is associated with airway-wall vascular remodelling and thickening in smokers with asthma
    Authors: D Wu, T Lai, Y Yuan, M Chen, J Xia, W Li, G Pan, B Yuan, Q Lv, Y Li, D Li, B Wu
    Sci Rep, 2017;7(0):43017.
    Species: Human
    Sample Type: Serum
  6. Predicting first trimester pregnancy outcome: derivation of a multiple marker test
    Authors: S Senapati, MD Sammel, SF Butts, P Takacs, K Chung, KT Barnhart
    Fertil. Steril., 2016;106(7):1725-1732.e3.
    Species: Human
    Sample Type: Serum
  7. Spectrum of Factors Triggering Endothelial Dysfunction in PIH
    Authors: VS Jammalamad, P Abraham
    J Clin Diagn Res, 2016;10(12):BC14-BC17.
    Species: Human
    Sample Type: Serum
  8. Neovascularization Potential of Blood Outgrowth Endothelial Cells From Patients With Stable Ischemic Heart Failure Is Preserved
    Authors: D Dauwe, B Pelacho, A Wibowo, AS Walravens, K Verdonck, H Gillijns, E Caluwe, P Pokreisz, N van Gastel, G Carmeliet, M Depypere, F Maes, N Vanden Dri, W Droogne, J Van Cleemp, J Vanhaecke, F Prosper, C Verfaillie, A Luttun, S Janssens
    J Am Heart Assoc, 2016;5(4):.
    Species: Human
    Sample Type: Cell Culture Supernates
  9. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia
    Authors: Ingrid C Weel
    PLoS ONE, 2016;11(6):e0157584.
    Species: Human
    Sample Type: Tissue Homogenates
  10. Inhibition of placental growth factor in renal cell carcinoma.
    Authors: Bessho H, Wong B, Huang D, Siew E, Huang D, Tan J, Ong C, Tan S, Matsumoto K, Iwamura M, Teh B
    Anticancer Res, 2015;35(1):531-41.
    Species: Human
    Sample Type: Cell Culture Supernates
  11. Reduction of maternal circulating endothelial progenitor cells in human pregnancies with intrauterine growth restriction.
    Authors: Calcaterra F, Taddeo A, Colombo E, Cappelletti M, Martinelli A, Calabrese S, Mavilio D, Cetin I, Della Bella S
    Placenta, 2014;35(7):431-6.
    Species: Human
    Sample Type: Plasma
  12. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury.
    Authors: White W, Garrett A, Craici I, Wagner S, Fitz-Gibbon P, Butters K, Brost B, Rose C, Grande J, Garovic V
    PLoS ONE, 2014;9(3):e92693.
    Species: Human
    Sample Type: Serum
  13. Placental growth factor and soluble Fms-like tyrosine kinase 1 in diabetic pregnancy: A possible relation to distal villous immaturity.
    Authors: El-Tarhouny S, Almasry S, Elfayomy A, Baghdadi H, Habib F
    Histol Histopathol, 2014;29(2):259-72.
    Species: Human
    Sample Type: Serum
  14. Elastase induces lung epithelial cell autophagy through placental growth factor: a new insight of emphysema pathogenesis.
    Authors: Hou H, Cheng S, Chung K, Kuo M, Yeh C, Chang B, Lu H, Wang H, Yu C
    Autophagy, 2014;10(9):1509-21.
    Species: Human
    Sample Type: Cell Culture Supernates
  15. Advanced oxidation protein products enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts: a possible link between oxidative stress and preeclampsia.
    Authors: Huang Q, Wang S, Zhang M, Huang L, Tian J, Yu Y, Wang Z, Zhong M
    Placenta, 2013;34(10):949-52.
    Species: Human
    Sample Type: Cell Culture Supernates
  16. Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia.
    Authors: Liu, Linda Y, Yang, Ting, Ji, Jun, Wen, Qiaojun, Morgan, Alexande, Jin, Bo, Chen, Gongxing, Lyell, Deirdre, Stevenson, David K, Ling, Xuefeng, Butte, Atul J
    BMC Med, 2013;11(0):236.
    Species: Human
    Sample Type: Serum
  17. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis.
    Authors: Chaturvedi, Pallavi, Gilkes, Daniele, Wong, Carmen C, Luo, Weibo, Zhang, Huafeng, Wei, Hong, Takano, Naoharu, Schito, Luana, Levchenko, Andre, Semenza, Gregg L
    J Clin Invest, 2013;123(1):189-205.
    Species: Human
    Sample Type: Cell Culture Supernates
  18. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Authors: Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K
    BMC Cancer, 2012;12(0):37.
    Species: Human
    Sample Type: Tissue Homogenates
  19. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
    Br. J. Cancer, 2012;107(4):639-45.
    Species: Human
    Sample Type: Serum
  20. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
    Authors: Loupakis F, Cremolini C, Fioravanti A
    Br. J. Cancer, 2011;104(8):1262-9.
    Species: Human
    Sample Type: Plasma
  21. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
    Clin. Cancer Res., 2011;17(15):5113-22.
    Species: Human
    Sample Type: Plasma
  22. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.
    Authors: Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, Weitz J, Koch M
    BMC Cancer, 2011;11(0):286.
    Species: Human
    Sample Type: Serum
  23. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept.
    Authors: de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach JV
    Clin. Cancer Res., 2011;17(14):4872-4881.
    Species: Human
    Sample Type: Plasma
  24. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Authors: Powers RW, Jeyabalan A, Clifton RG
    PLoS ONE, 2010;5(10):e13263.
    Species: Human
    Sample Type: Serum
  25. Effect of smoking on circulating angiogenic factors in high risk pregnancies.
    Authors: Jeyabalan A, Powers RW, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Caritis S, Roberts JM, Kuller J, Cotroneo M, Kamon T, Mercer B, Ramsey R, Paul R, Rabello Y, McCart D, Mueller E, Goldenberg R, Copper R, Sorokin Y, Norman G, Millinder A, Christmas JT, McCoy S, Elder S, Elder N, Carter B, Pemberton V, Thurnau G, Meier A, Minton V, Meis P, Swain M, Moawad AH, Jones P, Iams JD, Meadows S, Brenner S, Collins B, Newman RB, Carter SG, Romero R, Sabo V, Thom E, Bain RP, MacPherson C, Johnson D, Fischer ML, McNellis D, Spong C, Catz C, Yaffe S
    PLoS ONE, 2010;5(10):e13270.
    Species: Human
    Sample Type: Serum
  26. Placental Growth Factor: A Promising Diagnostic Biomarker for Tubal Ectopic Pregnancy.
    Authors: Horne AW, Shaw JL
    J. Clin. Endocrinol. Metab., 2010;0(0):.
    Species: Human
    Sample Type: Serum
  27. Placenta growth factor in sickle cell disease: association with hemolysis and inflammation.
    Authors: Brittain JE, Hulkower B, Jones SK, Strayhorn D, De Castro L, Telen MJ, Orringer EP, Hinderliter A, Ataga KI
    Blood, 2010;115(10):2014-20.
    Species: Human
    Sample Type: Plasma
  28. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia.
    Authors: Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H
    Am. J. Obstet. Gynecol., 2010;202(2):161.e1-161.e1.
    Species: Human
    Sample Type: Serum
  29. Placental growth factor mediates aldosterone-dependent vascular injury in mice.
    Authors: Jaffe IZ, Newfell BG, Aronovitz M
    J. Clin. Invest., 2010;120(11):3891-900.
    Species: Human
    Sample Type: Tissue Homogenates
  30. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Authors: Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST
    Angiogenesis, 2010;13(4):337-47.
    Species: Human
    Sample Type: Cell Culture Supernates
  31. Human pregnancy specific beta-1-glycoprotein 1 (PSG1) has a potential role in placental vascular morphogenesis.
    Authors: Ha CT, Wu JA, Irmak S, Lisboa FA, Dizon AM, Warren JW, Ergun S, Dveksler GS
    Biol. Reprod., 2010;83(1):27-35.
    Species: Human
    Sample Type: Cell Culture Supernates
  32. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women.
    Authors: Cassidy A, Chiuve SE, Manson JE, Rexrode KM, Girman CJ, Rimm EB
    Arterioscler. Thromb. Vasc. Biol., 2009;29(1):134-9.
    Species: Human
    Sample Type: Plasma
  33. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis.
    Authors: Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E
    Fertil. Steril., 2008;89(4):922-6.
    Species: Human
    Sample Type: Serum
  34. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Authors: Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ
    J. Clin. Oncol., 2008;26(22):3743-8.
    Species: Human
    Sample Type: Plasma
  35. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
    Authors: Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD
    J. Am. Coll. Cardiol., 2008;52(5):387-93.
    Species: Human
    Sample Type: Plasma
  36. Endometrial NK cells are special immature cells that await pregnancy.
    Authors: Manaster I, Mizrahi S, Goldman-Wohl D, Sela HY, Stern-Ginossar N, Lankry D, Gruda R, Hurwitz A, Bdolah Y, Haimov-Kochman R, Yagel S, Mandelboim O
    J. Immunol., 2008;181(3):1869-76.
    Species: Human
    Sample Type: Cell Culture Supernates
  37. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.
    Authors: Jeyabalan A, Powers RW, Durica AR, Harger GF, Roberts JM, Ness RB
    Am. J. Hypertens., 2008;21(8):943-7.
    Species: Human
    Sample Type: Plasma
  38. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.
    Authors: Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M
    Exp. Hematol., 2008;36(8):1035-46.
    Species: Human
    Sample Type: Cell Culture Supernates
  39. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome.
    Authors: Apple FS, Pearce LA, Chung A, Ler R, Murakami MM
    Clin. Chem., 2007;53(5):874-81.
    Species: Human
    Sample Type: Plasma
  40. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure.
    Authors: Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, Heeschen C, Spyridopoulos I, Dimmeler S, Zeiher AM
    J. Am. Coll. Cardiol., 2007;49(24):2341-9.
    Species: Human
    Sample Type: Bone Marrow Plasma
  41. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction.
    Authors: Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D
    Clin. Sci., 2007;112(1):51-7.
    Species: Human
    Sample Type: Serum
  42. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis.
    Authors: Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y
    Am. J. Obstet. Gynecol., 2006;194(2):551-6.
    Species: Human
    Sample Type: Serum
  43. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Authors: Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA
    N. Engl. J. Med., 2006;355(10):992-1005.
    Species: Human
    Sample Type: Serum
  44. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.
    Authors: Iwama H, Uemura S, Naya N, Imagawa K, Takemoto Y, Asai O, Onoue K, Okayama S, Somekawa S, Kida Y, Takeda Y, Nakatani K, Takaoka M, Kawata H, Horii M, Nakajima T, Doi N, Saito Y
    J. Am. Coll. Cardiol., 2006;47(8):1559-67.
    Species: Human
    Sample Type: Plasma
  45. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential.
    Authors: Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T
    Am. J. Pathol., 2006;169(4):1167-82.
    Species: Human
    Sample Type: Tissue Homogenates
  46. Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells.
    Authors: Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB
    Glia, 2006;53(8):845-57.
    Species: Human
    Sample Type: Cell Culture Supernates
  47. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.
    Authors: Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA
    Am. J. Obstet. Gynecol., 2005;192(3):734-41.
    Species: Human
    Sample Type: Urine
  48. Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals.
    Authors: Briguori C, Testa U, Colombo A, Petrucci E, Condorelli G, Airoldi F, Peschle C, Condorelli G
    Am. J. Cardiol., 2005;97(4):472-6.
    Species: Human
    Sample Type: Serum
  49. Urinary placental growth factor and risk of preeclampsia.
    Authors: Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA
    JAMA, 2005;293(1):77-85.
    Species: Human
    Sample Type: Urine
  50. A potential pro-angiogenic cell therapy with human placenta-derived mesenchymal cells.
    Authors: Nishishita T, Ouchi K, Zhang X, Inoue M, Inazawa T, Yoshiura K, Kuwabara K, Nakaoka T, Watanabe N, Igura K, Takahashi TA, Yamashita N
    Biochem. Biophys. Res. Commun., 2004;325(1):24-31.
    Species: Human
    Sample Type: Cell Lysates
  51. Circulating angiogenic factors and the risk of preeclampsia.
    Authors: Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA
    N. Engl. J. Med., 2004;350(7):672-83.
    Species: Human
    Sample Type: Serum
  52. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
    Authors: Maynard SE, Min JY, Merchan J, Lim KH, Mondal S, Stillman IE, Epstein FH, Karumanchi SA
    J. Clin. Invest., 2003;111(5):649-58.
    Species: Human
    Sample Type: Serum
  53. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema.
    Authors: Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, Lee CN, Chen CA, Cheng WF, Wei SC, Yu CJ, Hsieh FJ, Hsu SM
    Am. J. Respir. Crit. Care Med., 2003;169(4):505-11.
    Species: Human
    Sample Type: Serum
  54. A critical role of placental growth factor in the induction of inflammation and edema formation.
    Authors: Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, Detmar M
    Blood, 2002;101(2):560-7.
    Species: Human
    Sample Type: Cell Lysates
  55. A longitudinal study of biochemical variables in women at risk of preeclampsia.
    Authors: Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L
    Am. J. Obstet. Gynecol., 2002;187(1):127-36.
  56. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.
    Authors: Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ
    Am. J. Pathol., 2002;160(4):1405-23.
    Species: Human
    Sample Type: Cell Culture Supernates
Expand to show all Citations

FAQs

  1. Does the Human PlGF Quantikine® ELISA Kit, Catalog # DPG00, detect free or total PlGF?

    • Soluble receptors or other binding proteins present in biological samples do not necessarily interfere with the measurement of ligands in samples. However, until the factors have been tested in the Quantikine® Immunoassay, the possibility of interference cannot be excluded. We cannot claim Catalog # DPG00 to be a "free" or "total" PlGF detecting kit, since all possible binding factors have not been tested. 

      Specificity testing performed using rhFlt-1/Fc (VEGF R1) for interference demonstrated interference at levels greater than 2000 pg/mL. Details of this testing can be found in the DPG00 product insert. Most samples will have lower levels of sFlt-1 than 2000 pg/ml.

View all ELISA FAQs
ELISA Controls
Description Application Cat# Citations Images  

Quantikine Immunoassay Control Group 7

Ctrl QC22  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....
Supplemental ELISA Products
Description Application Cat# Citations Images  

Quantikine ELISA Wash Buffer 1

ELISA WA126 6  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Have you used Human PlGF Quantikine ELISA Kit?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

Contact Us to Order
reload

Feedback

Customer Information
R&D Systems Guarantee